Crossbow Therapeutics, Inc.
June 25, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
At Crossbow Therapeutics, we develop T-cell engagers and complex biologics expanding the reach of antibody therapeutics.
The majority of our pipeline consists of TCEs targeting peptide-HLA (pHLA) complexes on cancer cells.
Our first program, CBX-250, is a TCE for a tumor-specific target (CG) in myeloid malignancies and is being evaluated in a Phase 1 study (NCT06994676).
Our second program, CBX-663, is a TCE targeting a pHLA from telomerase, a known oncogenic driver relevant to most cancer types. The FDA accepted our IND in May ’26, with FPI projected in Q3 ‘26.
Our third program, CBX-880, is a TCE targeting a pHLA from a cancer testis antigen, and has progressed to IND-enabling studies.
In addition to pHLA-targeted TCEs, we have developed an PD-L1 based immunomodulatory multi-specific antibody, with both potent single-agent activity, as well as universal combination potential with other agents, including TCEs.
Company HQ City:
Cambridge
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2021
Lead Product in Development:
CBX-250, Ph1 ongoing
CBX-663, IND accepted, FPI Q3 2026
CEO
CEO: Briggs Morrison
CSO: Dmitri Wiederschain
co-founder, SVP of Corporate Development and Operations: Geraldine Paulus
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
at least 3, possibly more
When you expect your next catalyst update?
End of 2026/early 2027
What is your next catalyst (value inflection) update?
PoC for CBX-250 (TCE for AML and CML)
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}